To synthesize current evidence on digital health technologies (DHTs) for monitoring and managing fatigue in individuals with inflammatory bowel disease (IBD).
Approach:
Key Findings:
Fatigue affects nearly 80% of patients with active IBD and persists in nearly half of those in clinical remission.
Current assessment methods for fatigue are inadequate, relying on infrequent questionnaires that do not capture daily fluctuations.
Digital health technologies have the potential to provide continuous symptom tracking and improve fatigue management.
Interpretation:
The existing evidence on DHTs for managing IBD-related fatigue is fragmented.
Limitations:
The review did not register a protocol as PROSPERO does not accept scoping reviews.
Implementation evidence was analyzed separately and not used to draw conclusions about patient-level outcomes.
Conclusion:
This scoping review provides a foundation for integrating data-driven fatigue care into routine IBD clinical practice.
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production